Jason C. Jones - 17 Feb 2022 Form 4 Insider Report for EKSO BIONICS HOLDINGS, INC. (EKSO)

Role
VP of Product Development
Signature
/s/ John F. Glenn, as attorney-in-fact
Issuer symbol
EKSO
Transactions as of
17 Feb 2022
Transactions value $
$0
Form type
4
Filing time
22 Feb 2022, 18:27:50 UTC
Previous filing
07 Apr 2022
Next filing
28 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EKSO Common Stock Award $0 +13.8K +19.34% $0.00 84.9K 17 Feb 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired pursuant to a restricted stock units award granted on March 3, 2021 that had both performance-based and time-based vesting conditions. The performance-based vesting conditions have been satisfied, and now the award is subject only to time-based vesting conditions. The award vests in three equal annual installments beginning on March 3, 2022.